A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older - Safety and Immunogenicity of V116 in Vaccine-Experienced Adults

Merck Sharp & Dohme LLC0 sites700 target enrollmentJune 3, 2022

ConditionsPneumococcal disease MedDRA version: 20.0Level: LLTClassification code 10035644Term: Pneumococcal infection NOSSystem Organ Class: 100000004862 Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Pneumococcal disease
Sponsor: Merck Sharp & Dohme LLC
Enrollment: 700
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

June 3, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Merck Sharp & Dohme LLC

Eligibility Criteria

Inclusion Criteria

•1\. The participant may have underlying chronic conditions if they are assessed to be stable as per the investigator’s judgment.
•2\. Is pneumococcal vaccine\-experienced, defined as prior receipt (\=1 year before enrollment) of PCV13, PCV15, PCV20, PPSV23, PCV13\+PPSV23, PPSV23\+PCV13, or PCV15\+PPSV23\.
•3\. Is male or female, \=50 years of age, at the time of informed consent.
•4\. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
•Not a WOCBP
•A WOCBP and:
•\- Uses an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long\-term and persistent basis), during the intervention period and for at least 6 weeks after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•\- Has a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
•\- Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a woman with an early undetected pregnancy.
•5\. The participant (or legally acceptable representative) has provided documented informed consent for the study. The participant may also provide documented informed consent for FBR and/or assay development sample collection. However, the participant may be enrolled in the study without providing consent for FBR or assay development sample collection.

Exclusion Criteria

•1\. Has a history of IPD (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture\-positive pneumococcal disease within 3 years of Visit 1 (Day 1\).
•2\. Has a known hypersensitivity to any component of V116, PCV15, PCV20, or PPSV23, including diphtheria toxoid.
•3\. Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented HIV infection, functional or anatomic asplenia, or history of autoimmune disease.
•4\. Has a coagulation disorder contraindicating intramuscular vaccination.
•5\. \*Had a recent febrile illness (defined as oral or tympanic temperature \=100\.4°F \[\=38\.0°C] or axillary or temporal temperature \=99\.4°F \[\=37\.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of study vaccine.
•6\. Has a known malignancy that is progressing or has required active treatment within the 3 years prior to signing the informed consent.
•7\. Received PPSV23 followed by either PCV15 or PCV20\.
•8\. \*Received systemic corticosteroids (prednisone equivalent of \=20 mg/day) for \=14 consecutive days and has not completed intervention \=14 days before receipt of study vaccine.
•9\. Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
•10\. \*Received any nonlive vaccine \=14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine \=30 days after receipt of any study vaccine. Exception: inactivated influenza vaccine and SARS\-CoV\-2 mRNA or protein subunit vaccine may be administered but must be given \=7 days before or \=15 days after receipt of study vaccine.